UBS Group AG - NYMOX PHARMACEUTICAL CORP ownership

NYMOX PHARMACEUTICAL CORP's ticker is NYMX and the CUSIP is P73398102. A total of 38 filers reported holding NYMOX PHARMACEUTICAL CORP in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of NYMOX PHARMACEUTICAL CORP
ValueSharesWeighting
Q2 2023$6,560
+5025.0%
34,530
+9108.0%
0.00%
Q1 2023$128
+6.7%
3750.0%0.00%
Q4 2022$1203750.0%0.00%
Q3 2022$0375
-59.5%
0.00%
Q2 2022$0
-100.0%
925
+68.2%
0.00%
Q1 2022$1,0000.0%5500.0%0.00%
Q4 2021$1,000
-85.7%
550
-83.5%
0.00%
Q3 2021$7,000
-12.5%
3,333
-36.2%
0.00%
Q2 2021$8,000
-81.0%
5,222
-72.6%
0.00%
Q1 2021$42,000
+50.0%
19,086
+65.9%
0.00%
Q4 2020$28,000
+600.0%
11,507
+615.2%
0.00%
Q3 2020$4,000
-91.8%
1,609
-88.3%
0.00%
Q2 2020$49,000
+1533.3%
13,729
+1112.8%
0.00%
Q1 2020$3,000
-40.0%
1,132
-47.4%
0.00%
Q4 2019$5,000
-16.7%
2,153
-31.1%
0.00%
Q3 2019$6,000
-14.3%
3,125
-38.4%
0.00%
Q2 2019$7,000
-50.0%
5,069
-26.5%
0.00%
Q1 2019$14,000
-12.5%
6,897
-42.3%
0.00%
Q4 2018$16,000
-33.3%
11,947
+21.4%
0.00%
Q3 2018$24,000
+71.4%
9,840
+138.7%
0.00%
Q2 2018$14,000
+180.0%
4,123
+262.6%
0.00%
Q1 2018$5,000
-64.3%
1,137
-73.2%
0.00%
Q4 2017$14,000
-26.3%
4,235
-17.3%
0.00%
Q3 2017$19,000
-89.9%
5,123
-88.1%
0.00%
Q2 2017$189,000
+256.6%
43,091
+196.8%
0.00%
Q1 2017$53,000
+47.2%
14,518
+7.2%
0.00%
Q4 2016$36,00013,542
+16618.5%
0.00%
Q2 2016$081
+5.2%
0.00%
Q1 2016$0770.00%
Other shareholders
NYMOX PHARMACEUTICAL CORP shareholders Q3 2021
NameSharesValueWeighting ↓
First Citizens Financial Corp 35,100$44,0000.03%
Brown Advisory Securities, LLC 28,000$35,0000.02%
Murchinson Ltd. 76,404$96,0000.02%
WEBSTER BANK, N. A. 80,000$101,0000.01%
Patriot Financial Group Insurance Agency, LLC 34,650$44,0000.01%
WMS Partners, LLC 42,000$53,0000.01%
Willow Creek Wealth Management Inc. 18,724$24,0000.01%
Cubic Asset Management, LLC 14,000$18,0000.00%
CVI Holdings, LLC 45,993$58,0000.00%
One Day In July LLC 10,000$13,0000.00%
View complete list of NYMOX PHARMACEUTICAL CORP shareholders